AR093446A1 - Anticuerpos de antihemaglutinina y metodos de uso - Google Patents
Anticuerpos de antihemaglutinina y metodos de usoInfo
- Publication number
- AR093446A1 AR093446A1 ARP130104146A ARP130104146A AR093446A1 AR 093446 A1 AR093446 A1 AR 093446A1 AR P130104146 A ARP130104146 A AR P130104146A AR P130104146 A ARP130104146 A AR P130104146A AR 093446 A1 AR093446 A1 AR 093446A1
- Authority
- AR
- Argentina
- Prior art keywords
- antibodies
- methods
- antihemaglutinine
- antihemagglutinin
- compositions
- Prior art date
Links
- 239000000203 mixture Substances 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1018—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
- A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Abstract
Anticuerpos de antihemaglutinina, composiciones que comprenden anticuerpos de antihemaglutinina y sus métodos de uso. Ácido nucleico y célula huésped.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261725859P | 2012-11-13 | 2012-11-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR093446A1 true AR093446A1 (es) | 2015-06-10 |
Family
ID=50693943
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP130104146A AR093446A1 (es) | 2012-11-13 | 2013-11-12 | Anticuerpos de antihemaglutinina y metodos de uso |
Country Status (24)
Country | Link |
---|---|
US (5) | US9284365B2 (es) |
EP (2) | EP3461501A1 (es) |
JP (2) | JP6386465B2 (es) |
KR (1) | KR20150083124A (es) |
CN (1) | CN104968367B (es) |
AR (1) | AR093446A1 (es) |
AU (1) | AU2013345072B2 (es) |
BR (1) | BR112015010817A8 (es) |
CA (1) | CA2890669A1 (es) |
CL (1) | CL2015001266A1 (es) |
CR (1) | CR20150247A (es) |
EA (2) | EA201892509A1 (es) |
ES (1) | ES2701746T3 (es) |
HK (1) | HK1215856A1 (es) |
IL (2) | IL238684A0 (es) |
MA (1) | MA38176A1 (es) |
MX (2) | MX2015005860A (es) |
PE (1) | PE20150945A1 (es) |
PH (1) | PH12015501059A1 (es) |
SG (2) | SG10201700488QA (es) |
TW (2) | TWI657095B (es) |
UA (1) | UA116999C2 (es) |
WO (1) | WO2014078268A2 (es) |
ZA (1) | ZA201503403B (es) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3255110B1 (en) | 2011-07-08 | 2022-08-17 | Seiko Epson Corporation | Photocurable ink composition for ink jet recording and ink jet recording method |
MA38176A1 (fr) * | 2012-11-13 | 2017-06-30 | Genentech Inc | Nouvel anticorps anti-hemagglutinine, utile pour le traitement, l'inhibition ou la prévention de l’infection virale a grippe a |
SG11201602522VA (en) | 2013-10-02 | 2016-04-28 | Medimmune Llc | Neutralizing anti-influenza a antibodies and uses thereof |
RU2682049C2 (ru) * | 2014-01-27 | 2019-03-14 | Дженентек, Инк. | Лечение вируса гриппа а h7n9 |
CN106573154B (zh) | 2014-07-15 | 2021-06-15 | 免疫医疗有限责任公司 | 中和抗乙型流感抗体及其用途 |
TWI701258B (zh) | 2014-12-19 | 2020-08-11 | 美商再生元醫藥公司 | 流行性感冒病毒血球凝集素之人類抗體 |
US11135282B2 (en) * | 2015-04-08 | 2021-10-05 | Dana-Farber Cancer Institute, Inc. | Humanized influenza monoclonal antibodies and methods of use thereof |
DK3303384T3 (da) | 2015-06-01 | 2021-10-18 | Medimmune Llc | Neutraliserende anti-influenza-bindingsmolekyler og anvendelser deraf |
CN116271017A (zh) * | 2016-01-13 | 2023-06-23 | 免疫医疗有限责任公司 | 治疗甲型流感的方法 |
WO2017192589A1 (en) * | 2016-05-02 | 2017-11-09 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Neutralizing antibodies to influenza ha and their use and identification |
MX2019007433A (es) | 2016-12-22 | 2019-08-16 | Genentech Inc | Metodos y formulaciones para reducir el tiempo de reconstitucion de los polipeptidos liofilizados. |
WO2018170273A1 (en) | 2017-03-15 | 2018-09-20 | University Of Washington | De novo designed hemagglutinin binding proteins |
EP3625251A1 (en) * | 2017-05-15 | 2020-03-25 | University Of Rochester | Broadly neutralizing anti-influenza monoclonal antibody and uses thereof |
CN109666070B (zh) * | 2017-10-13 | 2021-02-19 | 清华大学 | 单克隆抗体mers-4v2及其编码基因和应用 |
EP3743442A1 (en) | 2018-01-26 | 2020-12-02 | Regeneron Pharmaceuticals, Inc. | Human antibodies to influenza hemagglutinin |
MX2021001769A (es) * | 2018-08-14 | 2021-04-19 | Merck Sharp & Dohme Llc | Un ensayo de neutralizacion de virus utilizando citometria de imagenes. |
WO2020093159A1 (en) * | 2018-11-06 | 2020-05-14 | Mcmaster University | Broadly-neutralizing antibody and neuraminidase inhibitor combinations to prevent or treat influenza virus infections |
JP2023544143A (ja) * | 2020-09-29 | 2023-10-20 | イノベント バイオロジクス(シンガポール)プライベート リミティド | 抗クローディン18.2および抗cd3二重特異性抗体およびその使用 |
Family Cites Families (111)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4737456A (en) | 1985-05-09 | 1988-04-12 | Syntex (U.S.A.) Inc. | Reducing interference in ligand-receptor binding assays |
US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・2・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
US5770701A (en) | 1987-10-30 | 1998-06-23 | American Cyanamid Company | Process for preparing targeted forms of methyltrithio antitumor agents |
US5606040A (en) | 1987-10-30 | 1997-02-25 | American Cyanamid Company | Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group |
EP0368684B2 (en) | 1988-11-11 | 2004-09-29 | Medical Research Council | Cloning immunoglobulin variable domain sequences. |
DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
CA2026147C (en) | 1989-10-25 | 2006-02-07 | Ravi J. Chari | Cytotoxic agents comprising maytansinoids and their therapeutic use |
US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
DK0564531T3 (da) | 1990-12-03 | 1998-09-28 | Genentech Inc | Berigelsesfremgangsmåde for variantproteiner med ændrede bindingsegenskaber |
US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
LU91067I2 (fr) | 1991-06-14 | 2004-04-02 | Genentech Inc | Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines |
GB9114948D0 (en) | 1991-07-11 | 1991-08-28 | Pfizer Ltd | Process for preparing sertraline intermediates |
CA2116774C (en) | 1991-09-19 | 2003-11-11 | Paul J. Carter | Expression in e. coli antibody fragments having at least a cysteine present as a free thiol. use for the production of bifunctional f(ab') 2 antibodies |
US5587458A (en) | 1991-10-07 | 1996-12-24 | Aronex Pharmaceuticals, Inc. | Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof |
WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
CA2372813A1 (en) | 1992-02-06 | 1993-08-19 | L.L. Houston | Biosynthetic binding protein for cancer marker |
US5589174A (en) | 1992-09-17 | 1996-12-31 | Takara Shuzo Co., Ltd. | Anti-human influenza virus antibody |
JP3095175B2 (ja) | 1992-11-13 | 2000-10-03 | アイデック ファーマシューティカルズ コーポレイション | B細胞リンパ腫の治療のためのヒトbリンパ球限定分化抗原に対するキメラ抗体と放射能標識抗体の療法利用 |
US5635483A (en) | 1992-12-03 | 1997-06-03 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Tumor inhibiting tetrapeptide bearing modified phenethyl amides |
US5780588A (en) | 1993-01-26 | 1998-07-14 | Arizona Board Of Regents | Elucidation and synthesis of selected pentapeptides |
WO1994029351A2 (en) | 1993-06-16 | 1994-12-22 | Celltech Limited | Antibodies |
US5773001A (en) | 1994-06-03 | 1998-06-30 | American Cyanamid Company | Conjugates of methyltrithio antitumor agents and intermediates for their synthesis |
US5789199A (en) | 1994-11-03 | 1998-08-04 | Genentech, Inc. | Process for bacterial production of polypeptides |
US5840523A (en) | 1995-03-01 | 1998-11-24 | Genetech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
US5712374A (en) | 1995-06-07 | 1998-01-27 | American Cyanamid Company | Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates |
US5714586A (en) | 1995-06-07 | 1998-02-03 | American Cyanamid Company | Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates |
US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
GB9603256D0 (en) | 1996-02-16 | 1996-04-17 | Wellcome Found | Antibodies |
US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
WO1998058964A1 (en) | 1997-06-24 | 1998-12-30 | Genentech, Inc. | Methods and compositions for galactosylated glycoproteins |
US6040498A (en) | 1998-08-11 | 2000-03-21 | North Caroline State University | Genetically engineered duckweed |
WO1999022764A1 (en) | 1997-10-31 | 1999-05-14 | Genentech, Inc. | Methods and compositions comprising glycoprotein glycoforms |
US6610833B1 (en) | 1997-11-24 | 2003-08-26 | The Institute For Human Genetics And Biochemistry | Monoclonal human natural antibodies |
IL136544A0 (en) | 1997-12-05 | 2001-06-14 | Scripps Research Inst | Humanization of murine antibody |
CA2323757C (en) | 1998-04-02 | 2011-08-02 | Genentech, Inc. | Antibody variants and fragments thereof |
US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
DK1071700T3 (da) | 1998-04-20 | 2010-06-07 | Glycart Biotechnology Ag | Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet |
EP1141024B1 (en) | 1999-01-15 | 2018-08-08 | Genentech, Inc. | POLYPEPTIDE COMPRISING A VARIANT HUMAN IgG1 Fc REGION |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
DK2270150T4 (da) | 1999-04-09 | 2019-08-26 | Kyowa Hakko Kirin Co Ltd | Fremgangsmåde til at kontrollere aktiviteten af immunologisk funktionelt molekyle. |
US7125978B1 (en) | 1999-10-04 | 2006-10-24 | Medicago Inc. | Promoter for regulating expression of foreign genes |
MXPA02003456A (es) | 1999-10-04 | 2002-10-23 | Medicago Inc | Metodo para regular la transcripcion de genes foraneos. |
CA2388245C (en) | 1999-10-19 | 2012-01-10 | Tatsuya Ogawa | The use of serum-free adapted rat cells for producing heterologous polypeptides |
EP1240319A1 (en) | 1999-12-15 | 2002-09-18 | Genentech, Inc. | Shotgun scanning, a combinatorial method for mapping functional protein epitopes |
CA2395660A1 (en) | 1999-12-29 | 2001-07-12 | Immunogen, Inc. | Cytotoxic agents comprising modified doxorubicins and daunorubicins and their therapeutic use |
CN101289511A (zh) | 2000-04-11 | 2008-10-22 | 杰南技术公司 | 多价抗体及其应用 |
US7064191B2 (en) | 2000-10-06 | 2006-06-20 | Kyowa Hakko Kogyo Co., Ltd. | Process for purifying antibody |
PL218428B1 (pl) | 2000-10-06 | 2014-12-31 | Kyowa Hakko Kogyo Kk | Komórka, sposoby wytwarzania przeciwciał, leki zawierające przeciwciała, komórka CHO i przeciwciało klasy IgG |
US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
DE60131456T2 (de) | 2000-11-30 | 2008-07-10 | Medarex, Inc., Milpitas | Transchromosomale transgen-nagetiere zur herstellung von humanen antikörpern |
FR2817869B1 (fr) | 2000-12-07 | 2005-01-14 | Technopharm | Anticorps monoclonal humain dirige contre le virus influenza ou un fragment de celui-ci |
KR20100018071A (ko) | 2001-08-03 | 2010-02-16 | 글리카트 바이오테크놀로지 아게 | 항체 의존적 세포 독성이 증가된 항체 글리코실화 변이체 |
KR100988949B1 (ko) | 2001-10-25 | 2010-10-20 | 제넨테크, 인크. | 당단백질 조성물 |
US20040093621A1 (en) | 2001-12-25 | 2004-05-13 | Kyowa Hakko Kogyo Co., Ltd | Antibody composition which specifically binds to CD20 |
JPWO2003085118A1 (ja) | 2002-04-09 | 2005-08-11 | 協和醗酵工業株式会社 | 抗体組成物の製造方法 |
JPWO2003084569A1 (ja) | 2002-04-09 | 2005-08-11 | 協和醗酵工業株式会社 | 抗体組成物含有医薬 |
CA2481657A1 (en) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Cells of which genome is modified |
AU2003236018A1 (en) | 2002-04-09 | 2003-10-20 | Kyowa Hakko Kirin Co., Ltd. | METHOD OF ENHANCING ACTIVITY OF ANTIBODY COMPOSITION OF BINDING TO FcGamma RECEPTOR IIIa |
US20050031613A1 (en) | 2002-04-09 | 2005-02-10 | Kazuyasu Nakamura | Therapeutic agent for patients having human FcgammaRIIIa |
US7749753B2 (en) | 2002-04-09 | 2010-07-06 | Kyowa Hakko Kirin Co., Ltd | Cells in which activity of the protein involved in transportation of GDP-fucose is reduced or lost |
NZ556507A (en) | 2002-06-03 | 2010-03-26 | Genentech Inc | Synthetic antibody phage libraries |
US7361740B2 (en) | 2002-10-15 | 2008-04-22 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
ES2347241T3 (es) | 2002-12-16 | 2010-10-27 | Genentech, Inc. | Variantes de inmunoglobulina y sus utilizaciones. |
AU2004205631A1 (en) | 2003-01-16 | 2004-08-05 | Genentech, Inc. | Synthetic antibody phage libraries |
US20060104968A1 (en) | 2003-03-05 | 2006-05-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases |
US7871607B2 (en) | 2003-03-05 | 2011-01-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases |
EP1688439A4 (en) | 2003-10-08 | 2007-12-19 | Kyowa Hakko Kogyo Kk | HYBRID PROTEIN COMPOSITION |
AU2004280065A1 (en) | 2003-10-09 | 2005-04-21 | Kyowa Hakko Kirin Co., Ltd. | Process for producing antibody composition by using RNA inhibiting the function of alpha1,6-fucosyltransferase |
US9296820B2 (en) | 2003-11-05 | 2016-03-29 | Roche Glycart Ag | Polynucleotides encoding anti-CD20 antigen binding molecules with increased Fc receptor binding affinity and effector function |
ES2697327T3 (es) | 2003-11-06 | 2019-01-23 | Seattle Genetics Inc | Compuesto intermedio para la preparación de conjugados que comprenden derivados de auristatina y un enlazador |
WO2005053742A1 (ja) | 2003-12-04 | 2005-06-16 | Kyowa Hakko Kogyo Co., Ltd. | 抗体組成物を含有する医薬 |
CN1961003B (zh) | 2004-03-31 | 2013-03-27 | 健泰科生物技术公司 | 人源化抗TGF-β抗体 |
US7785903B2 (en) | 2004-04-09 | 2010-08-31 | Genentech, Inc. | Variable domain library and uses |
SG172616A1 (en) | 2004-04-13 | 2011-07-28 | Hoffmann La Roche | Anti-p-selectin antibodies |
TWI380996B (zh) | 2004-09-17 | 2013-01-01 | Hoffmann La Roche | 抗ox40l抗體 |
JP4948413B2 (ja) | 2004-09-23 | 2012-06-06 | ジェネンテック, インコーポレイテッド | システイン操作抗体および結合体 |
JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
EP2465870A1 (en) | 2005-11-07 | 2012-06-20 | Genentech, Inc. | Binding polypeptides with diversified and consensus VH/VL hypervariable sequences |
EP1973951A2 (en) | 2005-12-02 | 2008-10-01 | Genentech, Inc. | Binding polypeptides with restricted diversity sequences |
EP2016101A2 (en) | 2006-05-09 | 2009-01-21 | Genentech, Inc. | Binding polypeptides with optimized scaffolds |
DK2059533T3 (da) | 2006-08-30 | 2013-02-25 | Genentech Inc | Multispecifikke antistoffer |
MY170607A (en) | 2006-09-07 | 2019-08-20 | Crucell Holland Bv | Human binding molecules capable of neutralizing influenza virus h5n1 and uses thereof |
US20080226635A1 (en) | 2006-12-22 | 2008-09-18 | Hans Koll | Antibodies against insulin-like growth factor I receptor and uses thereof |
EP2125886A2 (en) | 2007-03-13 | 2009-12-02 | Humabs LLC | Antibodies against h5n1 strains of influenza a virus |
CN100592373C (zh) | 2007-05-25 | 2010-02-24 | 群康科技(深圳)有限公司 | 液晶显示面板驱动装置及其驱动方法 |
FR2921928B1 (fr) | 2007-10-08 | 2011-03-04 | Sanofi Pasteur | Anticorps monoclonaux specifiques de l'hemagglutinine du virus grippal |
DK2235064T3 (en) | 2008-01-07 | 2016-01-11 | Amgen Inc | A process for the preparation of heterodimeric Fc molecules using electrostatic control effects |
ITTO20080204A1 (it) | 2008-03-17 | 2009-09-18 | Pomona Biotechnologies Llc | Anticorpi monoclonali atti a reagire con una pluralita di sottotipi del virus influenzale a |
AU2009275226B2 (en) | 2008-07-25 | 2015-05-14 | Institute For Research In Biomedicine | Neutralizing anti-influenza a virus antibodies and uses thereof |
US8871207B2 (en) * | 2008-07-25 | 2014-10-28 | Humabs, LLC | Neutralizing anti-influenza A virus antibodies and uses thereof |
EP2380976A4 (en) | 2008-12-25 | 2012-11-07 | Univ Osaka | HUMAN ANTIBODY AGAINST HUMAN FLUX VIRUS |
KR101790354B1 (ko) | 2009-05-11 | 2017-10-25 | 얀센 백신스 앤드 프리벤션 비.브이. | 인플루엔자 바이러스 h3n2를 중화시킬 수 있는 인간 결합 분자 및 그것의 용도 |
CA2849668A1 (en) | 2010-03-08 | 2011-09-15 | Celltrion, Inc. | Human monoclonal antibodies derived from human b cells and having neutralizing activity against influenza a viruses |
EA029198B1 (ru) | 2010-03-26 | 2018-02-28 | Помона Ричерка С.Р.Л. | Полноразмерные иммуноглобулины изотипа igg, способные к распознаванию нейтрализующего эпитопа в области стебля гемагглютинина различных подтипов и их использование в качестве лекарственного средства против гриппа |
CN103209994B (zh) | 2010-06-17 | 2016-10-12 | 特瑞利斯生物科学有限责任公司 | 可用于被动流感免疫的抗体 |
WO2012021786A2 (en) | 2010-08-12 | 2012-02-16 | Theraclone Sciences, Inc. | Anti-hemagglutinin antibody compositions and methods of use thereof |
US9534042B2 (en) * | 2010-09-03 | 2017-01-03 | Fujita Health University | Influenza virus-neutralizing antibody and screening method therefor |
US9832528B2 (en) | 2010-10-21 | 2017-11-28 | Sony Corporation | System and method for merging network-based content with broadcasted programming content |
EP3812397A1 (en) | 2011-07-18 | 2021-04-28 | Institute for Research in Biomedicine | Neutralizing anti-influenza a virus antibodies and uses thereof |
MA38176A1 (fr) * | 2012-11-13 | 2017-06-30 | Genentech Inc | Nouvel anticorps anti-hemagglutinine, utile pour le traitement, l'inhibition ou la prévention de l’infection virale a grippe a |
-
2013
- 2013-11-12 MA MA38176A patent/MA38176A1/fr unknown
- 2013-11-12 KR KR1020157015422A patent/KR20150083124A/ko not_active Application Discontinuation
- 2013-11-12 EP EP18202063.6A patent/EP3461501A1/en not_active Withdrawn
- 2013-11-12 CN CN201380070209.9A patent/CN104968367B/zh not_active Expired - Fee Related
- 2013-11-12 WO PCT/US2013/069567 patent/WO2014078268A2/en active Application Filing
- 2013-11-12 SG SG10201700488QA patent/SG10201700488QA/en unknown
- 2013-11-12 TW TW106145139A patent/TWI657095B/zh not_active IP Right Cessation
- 2013-11-12 PE PE2015000619A patent/PE20150945A1/es not_active Application Discontinuation
- 2013-11-12 EP EP13854201.4A patent/EP2919813B1/en not_active Not-in-force
- 2013-11-12 TW TW102141135A patent/TWI613214B/zh not_active IP Right Cessation
- 2013-11-12 AU AU2013345072A patent/AU2013345072B2/en not_active Ceased
- 2013-11-12 MX MX2015005860A patent/MX2015005860A/es unknown
- 2013-11-12 CA CA2890669A patent/CA2890669A1/en not_active Abandoned
- 2013-11-12 EA EA201892509A patent/EA201892509A1/ru unknown
- 2013-11-12 BR BR112015010817A patent/BR112015010817A8/pt not_active Application Discontinuation
- 2013-11-12 SG SG11201503734UA patent/SG11201503734UA/en unknown
- 2013-11-12 AR ARP130104146A patent/AR093446A1/es unknown
- 2013-11-12 EA EA201590731A patent/EA201590731A1/ru unknown
- 2013-11-12 ES ES13854201T patent/ES2701746T3/es active Active
- 2013-11-12 JP JP2015541997A patent/JP6386465B2/ja not_active Expired - Fee Related
- 2013-11-12 US US14/077,414 patent/US9284365B2/en active Active
- 2013-12-11 UA UAA201504562A patent/UA116999C2/uk unknown
-
2014
- 2014-05-12 US US14/275,174 patent/US9067979B2/en active Active
-
2015
- 2015-05-07 IL IL238684A patent/IL238684A0/en unknown
- 2015-05-08 MX MX2019001026A patent/MX2019001026A/es unknown
- 2015-05-11 CL CL2015001266A patent/CL2015001266A1/es unknown
- 2015-05-11 CR CR20150247A patent/CR20150247A/es unknown
- 2015-05-13 PH PH12015501059A patent/PH12015501059A1/en unknown
- 2015-05-15 ZA ZA2015/03403A patent/ZA201503403B/en unknown
- 2015-05-29 US US14/725,508 patent/US9598481B2/en not_active Expired - Fee Related
-
2016
- 2016-02-12 US US15/042,436 patent/US9908931B2/en not_active Expired - Fee Related
- 2016-04-05 HK HK16103823.9A patent/HK1215856A1/zh not_active IP Right Cessation
-
2018
- 2018-01-18 US US15/874,758 patent/US20190023770A1/en not_active Abandoned
- 2018-02-13 JP JP2018022789A patent/JP6538216B2/ja not_active Expired - Fee Related
- 2018-11-27 IL IL263320A patent/IL263320A/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR093446A1 (es) | Anticuerpos de antihemaglutinina y metodos de uso | |
CY1125029T1 (el) | Τροποποιημενοι νουκλεοζιτες, νουκλεοτιδια, και νουκλεϊκα οξεα και χρησεις αυτων | |
CO2017005842A2 (es) | Anticuerpos heterodiméricos que se unen a cd3 y cd38 | |
CR20150462A (es) | Inhibidores de erk y sus usos | |
IL240881A0 (en) | Expression of the t cell balance gene, preparations, materials and methods for its use | |
AR095774A1 (es) | Anticuerpos anti-il-4 y anticuerpos biespecíficos y sus usos | |
PE20210107A1 (es) | Anticuerpos anti-cd3 y metodos de uso | |
BR112015001592A8 (pt) | análise de imagem e medidas de amostras biológicas | |
CL2015000582A1 (es) | Anticuerpos anti-mcam y métodos asociados de uso | |
AR090903A1 (es) | Anticuerpos e inmunoconjugados anti-pmel17 | |
CL2016001102A1 (es) | Anticuerpos anti-claudina novedosos y métodos de uso. | |
CR20150437A (es) | Construcciones de anticuerpos para cdh19 y cd3 | |
AR101845A1 (es) | Anticuerpos anti-her2 e inmunoconjugados | |
UY34484A (es) | Benzotienilo-pirrolotriazinas disustituidas y sus usos | |
BR112015007120A2 (pt) | anticorpo biespecífico, composição farmacêutica, uso, célula hospedeira e método de produção de um anticorpo | |
EA201590993A1 (ru) | Гетеродимерные иммуноглобулины | |
MX2016007541A (es) | Moléculas modificadas de ácido nucleico y usos de las mismas. | |
CR20140212A (es) | Anticuerpos anti-htra1 y métodos de uso | |
UY34815A (es) | Anticuerpos biespecíficos y sus métodos de uso | |
AR089752A1 (es) | Anticuerpos anti-lrp5 y metodos de uso | |
PE20190229A1 (es) | Anticuerpos anti-fcrn | |
UY34764A (es) | Derivados de 2,2-difluoropropionamida de metilo de bardoxolona, formas polimórficas y sus métodos de uso | |
EA201491947A1 (ru) | Антитела и иммуноконъюгаты к ly6e и способы применения | |
CL2017002514A1 (es) | Anticuerpos anti-c1s humanizados y métodos para usarlos. | |
MX2014014376A (es) | Anticuerpos de anti-biotina y metodos de uso. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |